Table 2.
Summary of clinical results.
| W0 (baseline) | W1 | W2 | W4 | |
|---|---|---|---|---|
| Modified ADAS | ||||
| CAP | 33.73 ± 20.70 | 21.56 ± 15.70 | 17.23 ± 18.10 | 13.12 ± 15.60 |
| p value | < 0.001* | |||
| Sham | 35.02 ± 14.80 | 28.45 ± 15.00 | 28.57 ± 18.70 | 27.39 ± 23.20 |
| p-value | = 0.114 | |||
| EASI | 4.24 ± 2.76 | 3.70 ± 2.18 | 3.05 ± 2.16 | 2.76 ± 2.13 |
| p value | = 0.002 | |||
| Number of patients showing improved IGA score | ||||
| CAP | N/A | 6 | 7 | 15 |
| Sham | N/A | 3 | 4 | 9 |
ADAS atopic dermatitis antecubital severity, CAP cold atmospheric plasma, EASI eczema area and severity index, IGA investigator’s global assessment.